IIA

Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London

Thursday, September 23, 2021 - 12:30pm

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.
  • The results which were published in February 2021, indicated that MDMA has the potential to be more effective at treating AUD.
  • This data will assist Awakn's progress by enabling a better design and more efficient execution of its clinical program.
  • Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.

The Institute Of Internal Auditors (IIA) Appoints Brad Monterio As Executive Vice President Of Member Competency And Learning

Tuesday, September 21, 2021 - 2:00pm

LAKE MARY, Fla., Sept. 21, 2021 /PRNewswire/ -- The Institute of Internal Auditors (IIA) announced the recent appointment of Brad Monterio to the global leadership team as Executive Vice President of Member Competency and Learning, a newly created position.

Key Points: 
  • LAKE MARY, Fla., Sept. 21, 2021 /PRNewswire/ -- The Institute of Internal Auditors (IIA) announced the recent appointment of Brad Monterio to the global leadership team as Executive Vice President of Member Competency and Learning, a newly created position.
  • His responsibilities also include the learning system for The IIA's premier global certification, Certified Internal Auditor (CIA), as well as sponsorships and advertising sales for the organization.
  • Prior to joining The IIA, Monterio was most recently Chief Learning Officer and Vice President of Member Competency and Learning for the California Society of CPAs, the largest state CPA society in the U.S., with approximately 45,000 members.
  • The Institute of Internal Auditors (IIA) is the internal audit profession's most widely recognized advocate, educator, and provider of standards, guidance, and certifications.

CertiProf is proud to announce its membership with the Professional Certification Coalition (PCC)

Thursday, September 16, 2021 - 2:00pm

SUNRISE, Fla., Sept. 16, 2021 /PRNewswire/ -- CertiProf, a leader in professional certifications, is proud to announce its membership with the Professional Certification Coalition (PCC), a D.C.-based nonprofit association that addresses legislative initiatives that directly impact professional certification programs and certified professionals.

Key Points: 
  • SUNRISE, Fla., Sept. 16, 2021 /PRNewswire/ -- CertiProf, a leader in professional certifications, is proud to announce its membership with the Professional Certification Coalition (PCC), a D.C.-based nonprofit association that addresses legislative initiatives that directly impact professional certification programs and certified professionals.
  • Being part of such an important coalition in the certification industry shows the broad international support that a badge issued by CertiProf has.
  • "CertiProf is excited to continue adding partnerships with strong organizations like the Professional Certification Coalition.
  • CertiProf is proud to assist the PCC in advocating for the professional certification industry as a whole and providing even greater value to CertiProf's lifelong learners.

Fintica AI completes financial market manipulation detection pilot for Israel Securities Authority

Tuesday, September 14, 2021 - 5:58pm

TEL AVIV, Israel, Sept. 14, 2021 /PRNewswire/ -- Israeli fintech artificial intelligence start-up, Fintica AI, Ltd., today announced the successful completion of a data analysis technology pilot for the Israel Securities Authority (ISA).

Key Points: 
  • TEL AVIV, Israel, Sept. 14, 2021 /PRNewswire/ -- Israeli fintech artificial intelligence start-up, Fintica AI, Ltd., today announced the successful completion of a data analysis technology pilot for the Israel Securities Authority (ISA).
  • Fintica AI is an Israeli fintech and deeptech company, which has developed disruptive autonomous artificial intelligence technology focused on the financial industry.
  • "Effective market surveillance technology is still a major issue in capital markets," said Philippe Metoudi CEO of Fintica AI.
  • Fintica AI is an Israeli Fintech & Deeptech company that is building next generation Autonomous AI for Capital Markets.

Fintica AI completes financial market manipulation detection pilot for Israel Securities Authority

Tuesday, September 14, 2021 - 5:46pm

TEL AVIV, Israel, Sept. 14, 2021 /PRNewswire/ -- Israeli fintech artificial intelligence start-up, Fintica AI, Ltd., today announced the successful completion of a data analysis technology pilot for the Israel Securities Authority (ISA).

Key Points: 
  • TEL AVIV, Israel, Sept. 14, 2021 /PRNewswire/ -- Israeli fintech artificial intelligence start-up, Fintica AI, Ltd., today announced the successful completion of a data analysis technology pilot for the Israel Securities Authority (ISA).
  • Fintica AI is an Israeli fintech and deeptech company, which has developed disruptive autonomous artificial intelligence technology focused on the financial industry.
  • "Effective market surveillance technology is still a major issue in capital markets," said Philippe Metoudi CEO of Fintica AI.
  • Fintica AI is an Israeli Fintech & Deeptech company that is building next generation Autonomous AI for Capital Markets.

Northstar Engages Boart Longyear for Miller Gold Drill Program and Closes Private Placement

Monday, September 13, 2021 - 9:00pm

Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.

Key Points: 
  • Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.
  • Northstar drilled 5,023 metres in 28 holes at Miller in 2020, targeting near-surface high-grade and bulk-tonnage gold-telluride mineralization at Miller.
  • Northstar also commissioned a $350,000 property-wide 3D IP, gravity and magnetic geophysics program on the Miller Gold Property in 2020 to further define gold mineralization controls at depth.
  • Northstar recently completed a 1,990 metre Phase IIA follow up diamond drill program at Miller on April 27th, 2021.

FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma

Thursday, September 9, 2021 - 12:30pm

The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders.

Key Points: 
  • The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders.
  • The marketing exclusivity that this broadened orphan drug designation imparts adds significantly to the existing patent estate surrounding hypericin."
  • In the first double-blind treatment cycle, 116 patients received HyBryte treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions.
  • In the second open-label treatment cycle (Cycle 2), all patients received HyBryte treatment of their index lesions.

Northstar Commences Surface Exploration at Miller Gold Property

Tuesday, August 17, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - Northstar Gold Corp. (CSE: NSG) (FSE: 3WV) ("Northstar" or the "Company"), announces that a surface exploration program including prospecting, mechanical stripping, geological mapping and channel sampling of selected areas was initiated at the Miller Gold Property on July 27th, 2021.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - Northstar Gold Corp. (CSE: NSG) (FSE: 3WV) ("Northstar" or the "Company"), announces that a surface exploration program including prospecting, mechanical stripping, geological mapping and channel sampling of selected areas was initiated at the Miller Gold Property on July 27th, 2021.
  • Surface stripping has proven to be highly effective in defining new mineralized zones on the Miller Gold Property as overburden is generally thin.
  • The Company's flagship property is the 100% owned Miller Gold Property, situated 18 km southeast of Kirkland Lake and Kirkland Lake Gold's Macassa SMC gold mine.
  • Northstar's flagship property is the 100% owned Miller Gold Property, situated 18 km southeast of Kirkland Lake and Kirkland Lake Gold's Macassa SMC gold mine.

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

Tuesday, August 17, 2021 - 1:00pm

IRVINE, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to provide clear insights that inform critical decisions in cancer treatment, announced today the launch of a nationwide, prospective, real-world (RW) registry for patients with potentially curable early-stage lung cancer. The study is entitled the Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry.

Key Points: 
  • This registry was created to collect data that may demonstrate the impact of biomarker-guided treatment decisions on patients with completely resected stage I and IIA non-squamous non-small cell lung cancer across multiple academic and community cancer centers in the United States.
  • Biomarker tests are playing an increasingly important role in guiding cancer treatment.
  • The PADMA Registry, which utilizes Oncocytes DetermaRxTM test, will be the first RW initiative to evaluate the use of biomarkers in early-stage lung cancer.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.

BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update

Monday, August 16, 2021 - 11:30am

NESS ZIONA, Israel, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2021.

Key Points: 
  • NESS ZIONA, Israel, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2021.
  • In May 2021, BiomX announced completion of enrollment in its Phase 2 cosmetic clinical study of BX001.
  • BiomX expects to report results from preclinical in vivo studies evaluating the use of phage therapy for colorectal cancer in the fourth quarter of 2021.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter 2021 ended June 30, 2021.